Critical signal transduction pathways in CLL

Advances in Experimental Medicine and Biology

Volumn 792, Issue , 2013, Pages 215-239

  Ghosh, Asish K ^a   Kay, Neil E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Apoptosis; CLL; Kinase inhibitor; Non RTK; RTK; Signal transduction; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; BEVACIZUMAB; BGB 328; CEDIRANIB; CYTOKINE; DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FOSTAMATINIB; INSULIN RECEPTOR; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANOREXIA; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; BONE MARROW SUPPRESSION; BREAST TUMOR; CANCER FATIGUE; CELL ASSAY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; HYPERTENSION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUSCLE WEAKNESS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 84934439133     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8051-8_10     Document Type: Article

References (151)

1. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Rev Clin Oncol. 2009;6(7):405-18.
2. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005;19(4):513-23.
3. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011;117(6):1928-37 [In Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
4. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396-404 [Research Support, N.I.H., Intramural].
5. Veronese L, Tournilhac O, Verrelle P, Davi F, Dighiero G, Chautard E, et al. Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33(12):1623-6 [Research Support, Non-U.S. Gov't].
6. Schillaci R, Galeano A, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF. Autocrine/ paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol. 2005;130(1):58-66 [Research Support, Non-U.S. Gov't].
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-65 [Research Support, Non-U.S. Gov't Review].
8. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326-39 [Research Support, Non-U.S. Gov't].
9. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-I regulates pro-B cell differentiation. Blood. 1992;80(5):1207-12 [Research Support, U.S. Gov't, P.H.S.].
10. Wang LM, Myers Jr MG, Sun XJ, Aaronson SA, White M, Pierce JH. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science. 1993;261(5128): 1591-4 [Research Support, U.S. Gov't, P.H.S.].
11. Rodriguez-Tarduchy G, Collins MK, Garcia I, Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 1992;149(2):535-40 [Research Support, Non-U.S. Gov't].
12. Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, et al. A reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis. J Clin Invest. 1994;94(1):320-7 [Research Support, U.S. Gov't, P.H.S.].
13. Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, et al. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology. 1992;131(5):2244-50.
14. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253(1):1-6 [Research Support, U.S. Gov't, P.H.S. Review].
15. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005;92(12):2097-101 [Research Support, Non-U.S. Gov't Review].
16. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-93 [Review].
17. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem. 1995;270(49):29176-81.
18. Kim B, Cheng HL, Margolis B, Feldman EL. Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling. J Biol Chem. 1998;273(51):34543-50 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
19. Beitner-Johnson D, LeRoith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem. 1995;270(10):5187-90 [Research Support, U.S. Gov't, P.H.S.].
20. D'Ambrosio C, Hongo A, Li S, Baserga R. The role of Grb2 in the growth and transformation of mouse embryo cells. Oncogene. 1996;12(2):371-8 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
21. Butler AA, Blakesley VA, Koval A, deJong R, Groffen J, LeRoith D. In vivo regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I. Differential effects on tyrosine phosphorylation and association with paxillin. J Biol Chem. 1997;272(44): 27660-4.
22. Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulinlike growth factor 1 receptor kinase. Nat Struct Biol. 2001;8(12):1058-63 [Research Support, U.S. Gov't, P.H.S.].
23. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000; 19(49):5574-81 [Research Support, U.S. Gov't, P.H.S. Review].
24. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4(10):591-602 [Review].
25. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(9):2679-92 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
26. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-71.
27. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90(22):10705-9 [In Vitro].
28. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res. 2004;2(6):315-26 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
29. Hughes DC. Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus. J Mol Evol. 2001;53(2):77-9.
30. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, et al. Ligandinduced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem. 2003;278(42):40973-9 [Research Support, Non-U.S. Gov't].
31. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569-79 [Review].
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
33. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer. 1999;79(5-6):965-70.
34. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol. 2006;33(2): 174-85 [Review].
35. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res. 2007;31(7):899-906.
36. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002;16(5):911-9.
37. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14(8):1414-8.
38. Szmigielska-Kaplon A, Lech-Maranda E, Jesionek-Kupnicka D, Gora-Tybor J, Blonski JZ, Kasznicki M, et al. Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(7):1351-3.
39. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002;100(9):3344-51.
40. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;107(3):605-10.
41. Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer. 2002;86(1):31-5.
42. Aguayo A, Manshouri T, O'Brien S, Keating M, Beran M, Koller C, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res. 2001;25(4):279-85.
43. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res. 2004;28(3):243-8.
44. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001;7(4):795-9.
45. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3- gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004;104(3):788-94.
46. Till KJ, Spiller DG, Harris RJ, Chen H, Zuzel M, Cawley JC. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood. 2005;105(12):4813-9.
47. Ugarte-Berzal E, Redondo-Munoz J, Eroles P, Del Cerro MH, Garcia-Marco JA, Terol MJ, et al. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood. 2010;115 (4):846-9.
48. Abrams ST, Brown BR, Zuzel M, Slupsky Jr. Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. Blood. 2010; 115(22):4447-54.
49. Shanafelt TD, Byrd JC, La PB, Zent CS, Call T, Secreto C, et al. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009;146(6):660-4.
50. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther. 2006;5(5):1099-107 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
51. Kreuter M, Woelke K, Bieker R, Schliemann C, Steins M, Buechner T, et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia. 2006;20(11): 1950-4 [Research Support, Non-U.S. Gov't].
52. Nowakowski GS, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res. 2008;32(10):1634-6.
53. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009;113(22):5568-74.
54. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, et al. Phase II trials of singleagent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(12):2222-9 [Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
55. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016-31 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
56. Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci. 2012;122(8):361-8 [Research Support, N.I.H., Extramural Review].
57. Faust M, Ebensperger C, Schulz AS, Schleithoff L, Hameister H, Bartram CR, et al. The murine ufo receptor: molecular cloning, chromosomal localization and in situ expression analysis. Oncogene. 1992;7(7):1287-93 [Research Support, Non-U.S. Gov't].
58. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994;84(6):1931-41 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
59. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature. 1999;398(6729):723-8 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
60. Schulz AS, Schleithoff L, Faust M, Bartram CR, Janssen JW. The genomic structure of the human UFO receptor. Oncogene. 1993;8(2):509-13.
61. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008;28(3):161-76 [Research Support, Non-U.S. Gov't].
62. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011;2(11):874-85 [Research Support, Non-U.S. Gov't].
63. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron. 1991;6(5):691-704 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
64. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7(2):215-21 [Research Support, Non-U.S. Gov't].
65. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene. 1995;10(12):2349-59 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
66. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995;60(6):791-7 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
67. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 1997;65(4):195-203.
68. Ito T, Ito M, Naito S, Ohtsuru A, Nagayama Y, Kanematsu T, et al. Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid. 1999;9(6):563-7.
69. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002;8(2):361-7.
70. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7(12):1058-64.
71. Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics. 1998;50(3):331-40 [Comparative Study Research Support, Non-U.S. Gov't].
72. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A. 2006;103(15): 5799-804 [Research Support, Non-U.S. Gov't].
73. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80(4):661-70.
74. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrestspecific gene 6. Nature. 1995;373(6515):623-6.
75. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006;17(4):295-304 [Review].
76. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res. 2006;98(11):1446-52 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
77. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res. 2007;100(4):502-9 [Comparative Study Research Support, Non-U.S. Gov't].
78. Melaragno MG, Fridell YW, Berk BC. The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med. 1999;9(8):250-3 [Review].
79. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115(9):1755-64.
80. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999-3004.
81. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007;7(11):819-22 [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review].
82. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801-8 [Research Support, Non-U.S. Gov't].
83. Ghosh AK, Boysen J, Price-troska T, Secreto C, Zent CS, Kay N. Axl receptor tyrosine kinase signaling pathway and the p53 tumor suppressor protein exist in a novel regulatory loop in B-cell chronic lymphocytic leukemia cells. ASH Annual Meeting Abstracts. 2011;118(21):799.
84. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984; 311(5981):29-33 [Research Support, U.S. Gov't, P.H.S.].
85. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 2008;17(7):997-1011 [Review].
86. Eksioglu-Demiralp E, Akdeniz T, Bayik M. Aberrant expression of c-met and HGF/c-met pathway provides survival advantage in B-chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2011;80(1):1-7 [Research Support, Non-U.S. Gov't].
87. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4(11):1383-8 [Research Support, Non-U.S. Gov't].
88. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915-25 [Review].
89. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225(1):1-26 [Review].
90. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53(1):35-69 [Review].
91. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 2003;100(21):12039-44 [In Vitro Research Support, Non-U.S. Gov't].
92. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77(2):261-71 [Research Support, Non-U.S. Gov't].
93. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373(6516):702-5 [Research Support, Non-U.S. Gov't].
94. Sugiura K, Taketani S, Yoshimura T, Nishino T, Nishino N, Fujisawa J, et al. Effect of hepatocyte growth factor on long term hematopoiesis of human progenitor cells in transgenicsevere combined immunodeficiency mice. Cytokine. 2007;37(3):218-26 [Research Support, Non-U.S. Gov't].
95. Chan PC, Chen SY, Chen CH, Chen HC. Crosstalk between hepatocyte growth factor and integrin signaling pathways. J Biomed Sci. 2006;13(2):215-23 [Research Support, Non-U.S. Gov't Review].
96. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1-41 [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
97. Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res. 2002;11(1):19-32 [Research Support, Non-U.S. Gov't Review].
98. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-29 [Review].
99. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013-23 [Research Support, Non-U.S. Gov't].
100. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009;8 (21):2042-50 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
101. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9(2):R23 [Research Support, Non-U.S. Gov't].
102. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68(7):2340-8.
103. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res. 2007;13(10):3051-7 [Research Support, Non-U.S. Gov't].
104. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of t (4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcriptionpolymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 2000; 60(15):4058-61 [Comparative Study Research Support, Non-U.S. Gov't].
105. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-34 [Research Support, U.S. Gov't, P.H.S.].
106. Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36(9):793-6 [Research Support, Non-U.S. Gov't].
107. Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, et al. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther. 2011;10(9):1542-52 [Research Support, Non-U.S. Gov't].
108. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119(11):3395-407 [Research Support, N.I.H., Extramural].
109. Wang JK, Gao G, Goldfarb M. Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol. 1994;14(1):181-8 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
110. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7(3):165-97 [Review].
111. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood. 1996;87(3):1056-63.
112. Krejci P, Dvorakova D, Krahulcova E, Pachernik J, Mayer J, Hampl A, et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia. 2001;15(2):228-37 [Research Support, Non-U.S. Gov't].
113. Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005;106(13): 4303-7.
114. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;113(2):400-6.
115. Konig A, Menzel T, Lynen S, Wrazel L, Rosen A, Al-Katib A, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 1997;11(2):258-65.
116. Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen PY, Zhuang ZW, et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011; 121(7):2668-78 [Research Support, N.I.H., Extramural].
117. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639-47.
118. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 2008;18(11):536-44 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
119. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267(36):26181-90 [Comparative Study].
120. Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev. 2001; 105(1-2):153-6 [Research Support, Non-U.S. Gov't].
121. Oldridge M, Fortuna AM, Maringa M, Propping P, Mansour S, Pollitt C, et al. Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B. Nat Genet. 2000;24(3):275-8 [Research Support, Non-U.S. Gov't].
122. van Bokhoven H, Celli J, Kayserili H, van Beusekom E, Balci S, Brussel W, et al. Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome. Nat Genet. 2000;25(4):423-6 [Research Support, Non-U.S. Gov't].
123. Afzal AR, Rajab A, Fenske CD, Oldridge M, Elanko N, Ternes-Pereira E, et al. Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2. Nat Genet. 2000;25(4):419-22 [Research Support, Non-U.S. Gov't].
124. Ermakov S, Malkin I, Keter M, Kobyliansky E, Livshits G. Family-based association study of ROR2 polymorphisms with an array of radiographic hand bone strength phenotypes. Osteoporos Int. 2007;18(12):1683-92 [Research Support, Non-U.S. Gov't].
125. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625- 38.
126. Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res. 2003;23(1):1-15 [Research Support, Non-U.S. Gov't Review].
127. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008; 123(5):1190-5 [Research Support, Non-U.S. Gov't].
128. Reddy UR, Phatak S, Pleasure D. Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene. 1996; 13(7):1555-9 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
129. Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol. 2004; 41(6-7):631-43 [Review].
130. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23(48):7957-68 [Review].
131. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004;6(3):209-14 [Review].
132. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003;278(41):40057-66 [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
133. Belsches AP, Haskell MD, Parsons SJ. Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci. 1997;2:d501-18 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
134. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-7 [Review].
135. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223(1):14-26 [Review].
136. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat. 2010;13(3):67-78 [Review].
137. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct. 2011;2011:865819.
138. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115(2):369-78.
139. Kulathu Y, Hobeika E, Turchinovich G, Reth M. The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J. 2008;27(9):1333-44 [Research Support, Non-U.S. Gov't].
140. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21(3):148-54
141. Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood. 2001;97(4):1050-5 [Research Support, Non-U.S. Gov't].
142. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20(2):313-8.
143. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009;69(13):5424-32 [Research Support, Non-U.S. Gov't].
144. Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009; 28(37):3261-73 [Research Support, Non-U.S. Gov't].
145. Antic D, Jovanovic MP, Fekete MD, Cokic V. Assessment of bone marrow microvessel density in chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol. 2010; 18(4):353-6.
146. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol. 2008;3:16.
147. Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, Krawczynska A, Lech-Maranda E, Wierzbowska A, et al. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(1): 62-7.
148. Martinelli S, Maffei R, Castelli I, Santachiara R, Zucchini P, Fontana M, et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res. 2008;32(4):593-7.
149. Quiney C, Billard C, Mirshahi P, Fourneron JD, Kolb JP. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia. 2006;20(4):583-9.
150. Smolej L, Andrys C, Krejsek J, Belada DZ, Zak P, Siroky O, et al. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment]. Vnitr Lek. 2007;53(11):1171-6.
151. Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res. 2010;16(13):3390-8.